Aurinia Pharmaceuticals Inc. (AUPH) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Win.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Win.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
36/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 9 wins, 3 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
LoseAUPH / S&P 14.51% / 15.20% |
WinAUPH / S&P 19.76% / 15.00% |
WinAUPH / S&P 430.23% / 50.40% |
| 2026-Q12/3 |
LoseAUPH / S&P -7.08% / -4.33% |
WinAUPH / S&P 20.62% / 11.30% |
WinAUPH / S&P 671.43% / 27.70% |
| 2025-Q43/3 |
WinAUPH / S&P 44.34% / 2.65% |
WinAUPH / S&P 20.38% / 9.00% |
WinAUPH / S&P 4040.00% / 13.40% |
| 2025-Q32/3 |
WinAUPH / S&P 30.46% / 8.12% |
WinAUPH / S&P 20.62% / 4.61% |
LoseAUPH / S&P -500.00% / 13.45% |
| 2025-Q21/3 |
LoseAUPH / S&P 5.35% / 10.94% |
WinAUPH / S&P 25.59% / 4.83% |
LoseAUPH / S&P -230.30% / 10.63% |
| 2025-Q11/3 |
LoseAUPH / S&P -10.47% / -4.27% |
WinAUPH / S&P 29.20% / 4.98% |
LoseAUPH / S&P -166.67% / 10.57% |
| 2024-Q42/3 |
WinAUPH / S&P 22.51% / 2.41% |
WinAUPH / S&P 33.97% / 5.25% |
LoseAUPH / S&P -109.43% / 6.15% |
| 2024-Q32/3 |
WinAUPH / S&P 28.37% / 5.89% |
WinAUPH / S&P 38.72% / 5.89% |
LoseAUPH / S&P -73.58% / 6.11% |
| 2024-Q22/3 |
WinAUPH / S&P 13.97% / 4.28% |
WinAUPH / S&P 29.35% / 5.38% |
LoseAUPH / S&P -34.00% / 5.12% |
| 2024-Q11/3 |
LoseAUPH / S&P -44.27% / 10.56% |
WinAUPH / S&P 30.37% / 5.71% |
LoseAUPH / S&P -37.31% / 5.59% |
| 2023-Q42/3 |
WinAUPH / S&P 15.70% / 11.69% |
WinAUPH / S&P 30.95% / 6.81% |
LoseAUPH / S&P -30.26% / 7.78% |
| 2023-Q31/3 |
LoseAUPH / S&P -19.73% / -3.27% |
WinAUPH / S&P 23.14% / 7.52% |
LoseAUPH / S&P -36.14% / -5.03% |
| 2023-Q21/3 |
LoseAUPH / S&P -11.68% / 8.74% |
WinAUPH / S&P 82.19% / 9.50% |
LoseAUPH / S&P -56.90% / -8.57% |
| 2023-Q12/3 |
WinAUPH / S&P 153.70% / 7.50% |
WinAUPH / S&P 121.39% / 10.77% |
LoseAUPH / S&P -47.66% / -15.69% |
| 2022-Q41/3 |
LoseAUPH / S&P -42.55% / 7.56% |
WinAUPH / S&P 193.89% / 11.88% |
LoseAUPH / S&P -46.10% / -17.99% |
| 2022-Q31/3 |
LoseAUPH / S&P -25.17% / -4.88% |
WinAUPH / S&P 78.59% / 13.47% |
LoseAUPH / S&P -31.40% / -1.41% |
| 2022-Q21/3 |
LoseAUPH / S&P -18.82% / -16.10% |
WinAUPH / S&P 52.60% / 13.71% |
LoseAUPH / S&P 0.00% / 11.04% |
| 2022-Q11/3 |
LoseAUPH / S&P -45.87% / -4.60% |
WinAUPH / S&P 30.03% / 15.97% |
LoseAUPH / S&P 24.27% / 42.23% |
| 2021-Q40/3 |
LoseAUPH / S&P 3.34% / 11.03% |
LoseAUPH / S&P -9.00% / 15.00% |
LoseAUPH / S&P AUPH unavailable / 96.40% |
| 2021-Q31/3 |
WinAUPH / S&P 70.76% / 0.58% |
LoseAUPH / S&P AUPH unavailable / 10.77% |
LoseAUPH / S&P AUPH unavailable / 69.42% |
| 2021-Q20/3 |
LoseAUPH / S&P -0.19% / 8.55% |
LoseAUPH / S&P AUPH unavailable / 6.58% |
LoseAUPH / S&P AUPH unavailable / 51.81% |
| 2021-Q10/3 |
LoseAUPH / S&P -6.11% / 6.17% |
LoseAUPH / S&P AUPH unavailable / -1.06% |
LoseAUPH / S&P AUPH unavailable / 7.39% |
| 2020-Q40/3 |
LoseAUPH / S&P -6.11% / 12.15% |
LoseAUPH / S&P AUPH unavailable / -3.72% |
LoseAUPH / S&P AUPH unavailable / -33.42% |
| 2020-Q30/3 |
LoseAUPH / S&P -9.35% / 8.93% |
LoseAUPH / S&P AUPH unavailable / -2.04% |
LoseAUPH / S&P AUPH unavailable / -27.10% |
| 2020-Q20/3 |
LoseAUPH / S&P 11.99% / 20.54% |
LoseAUPH / S&P AUPH unavailable / -0.46% |
LoseAUPH / S&P AUPH unavailable / -27.11% |
| 2020-Q10/3 |
LoseAUPH / S&P -28.38% / -19.60% |
LoseAUPH / S&P AUPH unavailable / 3.47% |
LoseAUPH / S&P AUPH unavailable / -14.75% |
| 2019-Q41/3 |
WinAUPH / S&P 279.40% / 9.07% |
LoseAUPH / S&P AUPH unavailable / 5.36% |
LoseAUPH / S&P AUPH unavailable / 2.99% |
| 2019-Q30/3 |
LoseAUPH / S&P -18.84% / 1.70% |
LoseAUPH / S&P AUPH unavailable / 5.02% |
LoseAUPH / S&P AUPH unavailable / 0.21% |
| 2019-Q20/3 |
LoseAUPH / S&P 1.23% / 4.30% |
LoseAUPH / S&P AUPH unavailable / 6.64% |
LoseAUPH / S&P AUPH unavailable / 8.65% |
| 2019-Q10/3 |
LoseAUPH / S&P -4.69% / 13.65% |
LoseAUPH / S&P AUPH unavailable / 8.12% |
LoseAUPH / S&P AUPH unavailable / 14.29% |
| 2018-Q41/3 |
WinAUPH / S&P 2.71% / -13.52% |
LoseAUPH / S&P AUPH unavailable / 9.05% |
LoseAUPH / S&P AUPH unavailable / 18.23% |
| 2018-Q31/3 |
WinAUPH / S&P 17.94% / 7.71% |
LoseAUPH / S&P AUPH unavailable / 10.21% |
LoseAUPH / S&P AUPH unavailable / 19.06% |
| 2018-Q21/3 |
WinAUPH / S&P 8.48% / 3.43% |
LoseAUPH / S&P AUPH unavailable / 9.03% |
LoseAUPH / S&P AUPH unavailable / 14.46% |
| 2018-Q11/3 |
WinAUPH / S&P 14.57% / -0.76% |
LoseAUPH / S&P AUPH unavailable / 7.68% |
LoseAUPH / S&P AUPH unavailable / 12.46% |
| 2017-Q40/3 |
LoseAUPH / S&P -27.75% / 6.64% |
LoseAUPH / S&P AUPH unavailable / 7.03% |
LoseAUPH / S&P AUPH unavailable / 13.82% |
| 2017-Q30/3 |
LoseAUPH / S&P 2.28% / 4.48% |
LoseAUPH / S&P AUPH unavailable / 5.68% |
LoseAUPH / S&P AUPH unavailable / 17.57% |
| 2017-Q20/3 |
LoseAUPH / S&P -16.49% / 3.09% |
LoseAUPH / S&P AUPH unavailable / 4.83% |
LoseAUPH / S&P AUPH unavailable / 17.74% |
| 2017-Q11/3 |
WinAUPH / S&P 249.52% / 6.07% |
LoseAUPH / S&P AUPH unavailable / 3.67% |
LoseAUPH / S&P AUPH unavailable / 13.32% |
| 2016-Q40/3 |
LoseAUPH / S&P -30.23% / 3.82% |
LoseAUPH / S&P AUPH unavailable / 2.09% |
LoseAUPH / S&P AUPH unavailable / 7.05% |
| 2016-Q31/3 |
WinAUPH / S&P 8.66% / 3.85% |
LoseAUPH / S&P AUPH unavailable / 0.20% |
LoseAUPH / S&P AUPH unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | AUPH total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 37.41% | 20.78% |
| Annualized return | 37.41% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | AUPH total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -2.97% | 83.14% |
| Annualized return | -0.60% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | AUPH total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 744.87% | 319.30% |
| Annualized return | 23.79% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |